



# zymeworks

## Zymeworks Announces Presentations at the 2017 American Association for Cancer Research Annual Meeting

March 13, 2017

VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. ("Zymeworks"), a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer, today announced that it will be presenting at two sessions of the American Association for Cancer Research Annual Meeting, being held from April 1-5, 2017 in Washington, D.C.

Zymeworks will present at the following sessions:

**Abstract Title:** 31. Preclinical development of a novel biparatopic HER2 antibody with activity in low to high HER2-expressing cancers

**Session Information:** Antibodies, Bispecifics and Antibody-Drug Conjugates

**Date:** April 2, 2017

**Time:** 1:00 p.m. – 5:00 p.m. ET

**Abstract Title:** 61.ZymeLink drug conjugate platform: redefining the therapeutic window for ADCs

**Session Information:** Antibody Technology

**Date:** April 2, 2017

**Time:** 1:00 p.m. – 5:00 p.m. ET

Presentation abstracts are available on the AACR conference website at [www.aacr.org](http://www.aacr.org).

### About ZW25

ZW25 is Zymeworks' lead product candidate currently being evaluated in an adaptive Phase 1 clinical trial in the United States, based on Zymeworks' Azymetric platform. It is a bispecific antibody that can simultaneously bind two non-overlapping epitopes, known as biparatopic binding, of HER2 resulting in dual HER2 signal blockade, increased binding and removal of HER2 protein from the cell surface, and enhanced effector function. These combined mechanisms of action have led to significant anti-tumor activity in preclinical models of breast cancer. Zymeworks is developing ZW25 as a best-in-class HER2-targeting antibody intended as a treatment option for patients with any solid tumor that expresses HER2.

### About the ZymeLink Platform

The ZymeLink conjugation platform is a suite of novel site-specific protein coupling technologies and customizable cleavable linkers that allow for the delivery of Zymeworks' proprietary cytotoxic payloads, which can be applied to all of Zymeworks' antibody and albumin-based therapeutic platforms. Zymeworks believes that ZymeLink provides multiple competitive advantages over existing approaches, including optimized activity and tolerability profiles through increased drug delivery to target cells with reduced off-target effects, product homogeneity, preservation of immune cell interaction and stable pharmacokinetics.

### About Zymeworks Inc.

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer. Zymeworks' suite of complementary therapeutic platforms and its fully-integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly-differentiated product candidates. Zymeworks' lead product candidate, ZW25, is a novel bispecific antibody currently being evaluated in an adaptive Phase 1 clinical trial. Zymeworks is also advancing a deep pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other therapeutic areas. In addition to Zymeworks' wholly-owned pipeline, its therapeutic platforms have been further leveraged through multiple strategic partnerships with global biopharmaceutical companies.



View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20170313005383/en/>

Investor Inquiries:

Zymeworks Inc.

David Matousek, 604-678-1388

Senior Manager, Investor Relations & Corporate Communications

[\[email protected\]](#)

or

ICR Inc.

Stephanie Carrington, 646-277-1282

[\[email protected\]](#)

Source: Zymeworks Inc.